Literature DB >> 20307520

HDL in humans with cardiovascular disease exhibits a proteomic signature.

Tomás Vaisar1, Philip Mayer, Erik Nilsson, Xue-Qiao Zhao, Robert Knopp, Bryan J Prazen.   

Abstract

BACKGROUND: Alterations in protein composition and oxidative damage of high density lipoprotein (HDL) have been proposed to impair the cardioprotective properties of HDL. We tested whether relative levels of proteins in HDL(2) could be used as biomarkers for coronary artery disease (CAD).
METHODS: Twenty control and eighteen CAD subjects matched for HDL-cholesterol, age, and sex were studied. HDL(2) isolated from plasma was digested with trypsin and analyzed by high-resolution matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS) and pattern recognition analysis.
RESULTS: Partial least squares discriminant analysis (PLS-DA) of mass spectra clearly differentiated CAD from control subjects with area under the receiver operating characteristic curve (ROC(AUC)) of 0.94. Targeted tandem mass spectrometric analysis of the model's significant features revealed that HDL(2) of CAD subjects contained oxidized methionine residues of apolipoprotein A-I and elevated levels of apolipoprotein C-III. A proteomic signature composed of MALDI-MS signals from apoA-I, apoC-III, Lp(a) and apoC-I accurately classified CAD and control subjects (ROC(AUC)=0.82).
CONCLUSIONS: HDL(2) of CAD subjects carries a distinct protein cargo and that protein oxidation helps generate dysfunctional HDL. Moreover, models based on selected identified peptides in MALDI-TOF mass spectra of the HDL may have diagnostic potential. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20307520      PMCID: PMC2862883          DOI: 10.1016/j.cca.2010.03.023

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  42 in total

Review 1.  Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein.

Authors:  Baohai Shao; Michael N Oda; John F Oram; Jay W Heinecke
Journal:  Curr Opin Cardiol       Date:  2006-07       Impact factor: 2.161

Review 2.  The roles of multiple proteomic platforms in a pipeline for new diagnostics.

Authors:  N Leigh Anderson
Journal:  Mol Cell Proteomics       Date:  2005-07-14       Impact factor: 5.911

3.  Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL.

Authors:  Tomas Vaisar; Subramaniam Pennathur; Pattie S Green; Sina A Gharib; Andrew N Hoofnagle; Marian C Cheung; Jaeman Byun; Simona Vuletic; Sean Kassim; Pragya Singh; Helen Chea; Robert H Knopp; John Brunzell; Randolph Geary; Alan Chait; Xue-Qiao Zhao; Keith Elkon; Santica Marcovina; Paul Ridker; John F Oram; Jay W Heinecke
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

Review 4.  The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence.

Authors:  G Walldius; I Jungner
Journal:  J Intern Med       Date:  2006-05       Impact factor: 8.989

5.  Assessing the statistical validity of proteomics based biomarkers.

Authors:  Suzanne Smit; Mariëlle J van Breemen; Huub C J Hoefsloot; Age K Smilde; Johannes M F G Aerts; Chris G de Koster
Journal:  Anal Chim Acta       Date:  2007-04-27       Impact factor: 6.558

Review 6.  Narrative review: Assessment of C-reactive protein in risk prediction for cardiovascular disease.

Authors:  Donald M Lloyd-Jones; Kiang Liu; Lu Tian; Philip Greenland
Journal:  Ann Intern Med       Date:  2006-07-04       Impact factor: 25.391

Review 7.  ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease.

Authors:  John F Oram; Jay W Heinecke
Journal:  Physiol Rev       Date:  2005-10       Impact factor: 37.312

8.  Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women.

Authors:  Jacqueline Suk Danik; Nader Rifai; Julie E Buring; Paul M Ridker
Journal:  JAMA       Date:  2006-09-20       Impact factor: 56.272

Review 9.  Mechanisms of disease: proatherogenic HDL--an evolving field.

Authors:  Mohamad Navab; Gattadahalli M Anantharamaiah; Srinivasa T Reddy; Brian J Van Lenten; Benjamin J Ansell; Alan M Fogelman
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2006-09

Review 10.  Apolipoprotein A-I versus HDL cholesterol in the prediction of risk for myocardial infarction and stroke.

Authors:  Göran Walldius; Ingmar Jungner
Journal:  Curr Opin Cardiol       Date:  2007-07       Impact factor: 2.161

View more
  31 in total

1.  Antisense inhibition of apoB synthesis with mipomersen reduces plasma apoC-III and apoC-III-containing lipoproteins.

Authors:  Jeremy D Furtado; Mark K Wedel; Frank M Sacks
Journal:  J Lipid Res       Date:  2012-02-02       Impact factor: 5.922

2.  Serum amyloid A in uremic HDL promotes inflammation.

Authors:  Thomas Weichhart; Chantal Kopecky; Markus Kubicek; Michael Haidinger; Dominik Döller; Karl Katholnig; Cacang Suarna; Philipp Eller; Markus Tölle; Christopher Gerner; Gerhard J Zlabinger; Markus van der Giet; Walter H Hörl; Roland Stocker; Marcus D Säemann
Journal:  J Am Soc Nephrol       Date:  2012-01-26       Impact factor: 10.121

3.  Isoforms of apolipoprotein C-I associated with individuals with coronary artery disease.

Authors:  D'Vesharronne Moore; Catherine McNeal; Ronald Macfarlane
Journal:  Biochem Biophys Res Commun       Date:  2010-12-25       Impact factor: 3.575

4.  Discrimination of ischemic and hemorrhagic strokes using a multiplexed, mass spectrometry-based assay for serum apolipoproteins coupled to multi-marker ROC algorithm.

Authors:  Mary F Lopez; David A Sarracino; Amol Prakash; Michael Athanas; Bryan Krastins; Taha Rezai; Jennifer N Sutton; Scott Peterman; Oksana Gvozdyak; Sherry Chou; Eng Lo; Ferdinand Buonanno; MingMing Ning
Journal:  Proteomics Clin Appl       Date:  2012-04       Impact factor: 3.494

Review 5.  Biomedical mechanisms of blood stasis syndrome of coronary heart disease by systems biology approaches.

Authors:  Jie Wang; Gui Yu
Journal:  Chin J Integr Med       Date:  2013-08-05       Impact factor: 1.978

6.  Biochemical and functional characterization of charge-defined subfractions of high-density lipoprotein from normal adults.

Authors:  Ju-Yi Hsieh; Chiz-Tzung Chang; Max T Huang; Chia-Ming Chang; Chia-Ying Chen; Ming-Yi Shen; Hsin-Yi Liao; Guei-Jane Wang; Chu-Huang Chen; Chao-Jung Chen; Chao-Yuh Yang
Journal:  Anal Chem       Date:  2013-11-13       Impact factor: 6.986

7.  SAA: a link between cholesterol efflux capacity and inflammation?

Authors:  Michael J Thomas; Mary G Sorci-Thomas
Journal:  J Lipid Res       Date:  2015-06-15       Impact factor: 5.922

8.  High-density lipoproteins are a potential therapeutic target for age-related macular degeneration.

Authors:  Una L Kelly; Daniel Grigsby; Martha A Cady; Michael Landowski; Nikolai P Skiba; Jian Liu; Alan T Remaley; Mikael Klingeborn; Catherine Bowes Rickman
Journal:  J Biol Chem       Date:  2020-07-31       Impact factor: 5.157

Review 9.  Quantifying HDL proteins by mass spectrometry: how many proteins are there and what are their functions?

Authors:  Baohai Shao; Jay W Heinecke
Journal:  Expert Rev Proteomics       Date:  2017-11-13       Impact factor: 3.940

10.  Obesity favors apolipoprotein E- and C-III-containing high density lipoprotein subfractions associated with risk of heart disease.

Authors:  Beatriz Talayero; Liyun Wang; Jeremy Furtado; Vincent J Carey; George A Bray; Frank M Sacks
Journal:  J Lipid Res       Date:  2014-06-25       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.